表紙
市場調查報告書
商品編碼
838472

神經膠質母細胞瘤治療藥的全球市場:產業分析,市場規模·佔有率·成長率·趨勢·未來預測

Global Glioblastoma Treatment Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2018 to 2025

出版日期: | 出版商: Value Market Research | 英文 | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球神經膠母細胞瘤治療藥的市場相關分析,彙整疾病及治療方法概要和市場基本結構,主要的推動及阻礙市場要素,整體市場趨勢預測 (今後8年份),各類型·各流通管道·各地區的詳細趨勢,市場競爭環境,主要企業簡介等調查。

第1章 簡介

第2章 摘要整理

第3章 市場分析

  • 簡介
  • 價值鏈分析
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 波特的五力分析

第4章 神經膠質母細胞瘤治療藥市場分析:各類型

  • VEGF/VEGFR抑制劑
  • 烷化劑
  • 其他抗惡性腫瘤劑

第5章 神經膠質母細胞瘤治療藥市場分析:各流通管道

  • 醫院
  • 癌症研究組織
  • 長期治療中心
  • 診斷中心

第6章 神經膠質母細胞瘤治療藥市場分析:各地區

  • 北美市場 (美國,加拿大等)
    • 市場規模的估計價值
    • 市場規模的估計價值:各國
  • 歐洲市場 (英國,德國,法國等)
  • 亞太地區市場 (中國,日本,印度等)
  • 南美市場 (巴西等)
  • 中東·非洲市場

第7章 神經膠質母細胞瘤治療藥企業:競爭環境

  • 市場競爭
  • 事業聯盟/合作,協定
  • 企業合併·收購 (M&A)
  • 新產品的銷售
  • 其他動向

第8章 神經膠質母細胞瘤治療藥產業:企業簡介 (企業概要,財務分析,主要產品,近幾年趨勢)

  • Arbor Pharms LLC.
  • Bristol-Myers Squibb Company
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Sandoz
  • Sigma-Tau Pharmaceuticals, Inc.
  • Tentative TOC
目錄

The report on Global Glioblastoma Treatment Drugs Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2025. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).

  • Drivers
    • Rising prevalence of cancer among people
    • Growing advancement in molecular biotechnology field
  • Restraints
    • High cost of gliblastoma drugs

Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. This market is classified into different segments with detailed analysis of each with respect to geography for the study period:

  • Base Year: 2018
  • Estimated Year: 2019
  • Forecast Till: 2025

The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.

The report classifies the market into different segments based on type and distribution channel. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

The report also covers the complete competitive landscape of the worldwide market with company profiles of key players such as Arbor Pharms LLC., Bristol-Myers Squibb Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche AG, Merck & Co., Inc., Sandoz, and Sigma-Tau Pharmaceuticals, Inc., among others. A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.

SEGMENTATIONS IN THE REPORT:

By Type:

  • VEGF/VEGFR Inhibitor
  • Alkylating Agents
  • Miscellaneous Antineoplastic

By Distribution Channel:

  • Hospital
  • Cancer Research Organization
  • Long Term Care Center
  • Diagnostic Centers

By Geography:

  • North America (NA) - US, Canada & Rest of North America
  • Europe (EU) - UK, Germany, France & Rest of Europe
  • Asia Pacific (APAC) - China, Japan, India & Rest of APAC
  • Latin America (LA) - Brazil & Rest of Latin America
  • Middle East & Africa (MEA) - Middle East and Africa

Table of Contents

1. INTRODUCTION

  • Report Description
  • Research Scope
  • Research Methodology

2. EXECUTIVE SUMMARY

  • Market Highlight
  • Global Glioblastoma Treatment Drugs Market: Snapshot

3. MARKET ANALYSIS

  • Introduction
  • Value Chain Analysis
  • Drivers
  • Restraints
  • Opportunities
  • Porter's Five Forces Analysis

4. GLIOBLASTOMA TREATMENT DRUGS MARKET ANALYSIS BY TYPE

  • Market In VEGF/VEGFR Inhibitor
  • Market In Alkylating Agents
  • Market In Miscellaneous Antineoplastic

5. GLIOBLASTOMA TREATMENT DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • Market In Hospital
  • Market In Cancer Research Organization
  • Market In Long Term Care Center
  • Market In Diagnostic Centers

6. GLIOBLASTOMA TREATMENT DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • North America (NA)
  • North America Market Estimates
  • North America Market Estimates By Country
  • United States (U.S.)
  • Canada
  • Rest Of North America
  • Europe (EU)
  • Europe Market Estimates
  • Europe Market Estimates By Country
  • United Kingdom (UK)
  • Germany
  • France
  • Rest Of Europe
  • Asia Pacific (APAC)
  • Asia Pacific Market Estimates
  • Asia Pacific Market Estimates By Country
  • China
  • Japan
  • India
  • Rest Of Asia Pacific
  • Latin America (LA)
  • Latin America Market Estimates
  • Latin America Market Estimates By Country
  • Brazil
  • Rest Of Latin America
  • Middle East And Africa (MEA)
  • Middle East And Africa Market Estimates
  • Middle East And Africa Market Estimates By Country
  • Middle East
  • Africa

7. COMPETITIVE LANDSCAPE OF THE GLIOBLASTOMA TREATMENT DRUGS COMPANIES

  • Market Competition
  • Partnerships/Collaborations/Agreements
  • Mergers And Acquisitions
  • New Product Launches
  • Other Developments

8. COMPANY PROFILES OF THE GLIOBLASTOMA TREATMENT DRUGS INDUSTRY (Company Overview, Financial, Major Products & Recent Development)

  • Arbor Pharms LLC.
  • Bristol-Myers Squibb Company
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Sandoz
  • Sigma-Tau Pharmaceuticals, Inc.
  • Tentative TOC